122 related articles for article (PubMed ID: 20449626)
1. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
Lansiaux A; Salingue S; Dewitte A; Clisant S; Penel N
Invest New Drugs; 2012 Feb; 30(1):403-4. PubMed ID: 20449626
[TBL] [Abstract][Full Text] [Related]
2. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
[TBL] [Abstract][Full Text] [Related]
3. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
[TBL] [Abstract][Full Text] [Related]
4. Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care.
Penel N; Clisant S; Dansin E; Desauw C; Dégardin M; Mortier L; Vanhuyse M; Bonodeau F; Fournier C; Cazin JL; Adenis A
Br J Cancer; 2010 Apr; 102(8):1207-12. PubMed ID: 20354522
[TBL] [Abstract][Full Text] [Related]
5. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
Jia L; Waxman DJ
Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.
Borkamo ED; Fluge O; Mella O; Akslen LA; Bruland O; Dahl O
Radiother Oncol; 2008 Mar; 86(3):435-42. PubMed ID: 18313158
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
Penel N; Adenis A; Bocci G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):40-50. PubMed ID: 21641231
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Bocci G; Francia G; Man S; Lawler J; Kerbel RS
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12917-22. PubMed ID: 14561896
[TBL] [Abstract][Full Text] [Related]
11. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
12. Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.
Gillon P; Godbert Y; Dupin C; Bubien V; Italiano A; Roubaud G
Future Oncol; 2014 Nov; 10(14):2121-5. PubMed ID: 25471026
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.
Damber JE; Vallbo C; Albertsson P; Lennernäs B; Norrby K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):354-60. PubMed ID: 16333676
[TBL] [Abstract][Full Text] [Related]
14. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
15. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
[TBL] [Abstract][Full Text] [Related]
16. Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
Setyo L; Ma M; Bunn T; Wyatt K; Wang P
Vet Comp Oncol; 2017 Dec; 15(4):1468-1478. PubMed ID: 28194917
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
18. Metronomic oral cyclophosphamide in patients with advanced solid tumors.
Bojko P; Schimmel G; Bosse D; Abenhardt W
Onkologie; 2012; 35(1-2):35-8. PubMed ID: 22310343
[TBL] [Abstract][Full Text] [Related]
19. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma.
Lakkis Z; Kim S; Delabrousse E; Jary M; Nguyen T; Mantion G; Heyd B; Lassabe C; Borg C
J Hepatol; 2013 Jun; 58(6):1254-7. PubMed ID: 23402747
[TBL] [Abstract][Full Text] [Related]
20. An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report.
Gagliato Dde M; Linck RD; Bezerra RO; Souto M; Lopes GL; Baiocchi G; Mano MS
J Med Case Rep; 2016 Mar; 10():60. PubMed ID: 26971567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
